Product / Bevacizumab
Bevacizumab (MIL60) is the third drug approved for marketing by Betta Pharmaceuticals and the first approved large molecule biologic. In February 2017, Betta Pharmaceuticals entered into a collaboration with Beijing MAB Works Biotechnology Co., Ltd. for the bevacizumab injection project, and the entrusted manufacturer is Haizheng Biopharmaceutical Co., Ltd., a subsidiary of Zhejiang Borui Biopharmaceutical Co., Ltd. In December 2019, the phase III clinical study of bevacizumab injection (MIL60) reached the primary study endpoint. It is a randomized, double-blind, multicenter Phase III study comparing the efficacy and safety of MIL60 in combination with paclitaxel and carboplatin to bevacizumab in combination with paclitaxel and carboplatin for the treatment of subjects with advanced or recurrent non-squamous non-small cell lung cancer (NSCLC) in primary treatment, led by Professor Wang Jie of Cancer Hospital of Chinese Academy of Medical Sciences with the participation of 50 research centers across China. In June 2020, MIL60 marketing authorization application was accepted by the State Drug Administration. In September 2021, MIL60 Phase III clinical research results were presented at the 2021 European Society of Medical Oncology (ESMO) Annual Meeting. In November 2021, bevacizumab injection (MIL60) was officially approved for marketing, and the approved indications are metastatic colorectal cancer and advanced, metastatic or recurrent non-small cell lung cancer. In December 2021, the results of bevacizumab research were published in EClinicalMedicine, a subjournal of The Lancet. Four new indications (recurrent glioblastoma; hepatocellular carcinoma; epithelial ovarian, fallopian tube or primary peritoneal carcinoma; and cervical cancer) were accepted for application. In January 2022, the first order of bevacizumab was dispatched and the first prescriptions were written in several locations across China. In March 2022, several new indications for bevacizumab (indications for the treatment of patients with recurrent glioblastoma, epithelial ovarian, fallopian tube or primary peritoneal cancer, and cervical cancer) were approved.
|
|
